This research aims to provide robust preclinical evidence and establish optimal conditions that can inform clinical applications, thereby offering substantial insights into the therapeutic potential of ILA for neurodegenerative disorders like PD. The gene discussed is TNFRSF9; the disease is Parkinson disease.